A novel microfluidic device addresses one of the most costly steps in the engineered cell therapy manufacturing process, namely gene delivery. Deterministic mechanoporation, or DMP, uses fluid flow to pull each cell in a large population onto its own tiny needle. The flow is then reversed to release the cells from the needles, leaving a singular and precisely defined pore within each cell that allows for gene delivery. Eliminating viral vectors can substantially reduce cost.